

Heart Force Medical Wins Most Promising Pre-Commercial Technology Award at BCTIA

VANCOUVER, BC– June 18, 2009 – Heart Force Medical Inc. is developing the digital Ballistocardiograph (dBG™), a non-invasive medical device that assesses cardiac function. The Company is pleased to announce that it has been awarded the “Most Promising Pre-commercial Technology Award” by the British Columbia Technology Industry Association at its 2009 Technology Impact Awards held June 17, 2009.

This marks the sixteenth year for the British Columbia Technology Impact Awards (BCTIA). These awards recognize and celebrate exceptional leadership, innovation, and excellence within BC's diverse technology industry. The Most Promising Pre-Commercial Technology Award acknowledges a pre-commercial technology in the R&D stage of development with significant potential for commercialization and represents a fundamental advancement in technology. Last night's awards ceremony was attended by over 750 people. In excess of 90 companies submitted award applications to BCTIA. The awards ceremony was also attended by representatives from venture capital companies, investment banks and the Toronto Stock Exchange. This awards evening is the high point in the calendar for the BCTIA.

“I am thrilled to accept this award on behalf of our management team, our employees and our investors,” said Dr Geoff Houlton, Heart Force Medical's Chief Executive Officer. “We have made great strides in advancing what we believe is a breakthrough technology. The dBG™ will assist in the assessment of a patient's cardiac function, and ultimately will become an integral part of every patient's examination. Without the dedicated teamwork of all of the people at Heart Force Medical we would not be here today.”

Heart Force Medical Inc is developing the digital Ballistocardiograph (dBG™), a non-invasive medical device that assesses cardiac function by sensing forces generated from heart muscle contractions, relaying results via Bluetooth technology. The (dBG™) has already been approved in Canada and is in the final stage of certification in the FDA approval process for use in the United States.

For information regarding this press release, contact:

Dr Geoff Houlton
President & Chief Executive Officer
Tel: 778-989 7080
Email: geoff.houlton@heartforcemedical.com

Murray Oliver
Tel: 604-687 0888
Email: mjo@pemcorp.com
